tiprankstipranks
Trending News
More News >

Nova Eye Medical Achieves Record Revenues in FY25

Story Highlights
Nova Eye Medical Achieves Record Revenues in FY25

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Nova Eye Medical ( (AU:EYE) ).

Nova Eye Medical Limited has reported record revenues of A$28.8 million for the fiscal year ending June 30, 2025, marking a 21% increase from the previous year. This growth is attributed to the strong performance of their iTrack™ Advance device, particularly in the US market, where sales increased by 25%. The company anticipates continued revenue growth in FY26, reflecting the growing global recognition of its technology and successful market penetration.

More about Nova Eye Medical

Nova Eye Medical Limited is a medical technology company specializing in the development, manufacturing, and sale of proprietary ophthalmic treatment technologies and devices. Their products, including the iTrack™ Advance and Molteno3® glaucoma drainage device, are used globally by eye surgeons to treat glaucoma. The company operates sales headquarters in Fremont, California, and has manufacturing facilities in Fremont, California, and Dunedin, New Zealand.

Average Trading Volume: 378,524

Technical Sentiment Signal: Sell

Current Market Cap: A$35.52M

See more data about EYE stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1